Funding Opportunity RFA-HL-25-011 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 awardees for small grant support to expand their current research objectives or to branch out to a new study that resulted from the research conducted under the K award. Active NHLBI K01, K08, K23, and K25 awardees may apply for R03 support after the notices of award (NoA) for their first type-5 K awards have been issued. Recently completed NHLBI K01, K08, K23, and K25 awardees are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. This FOA is intended to enhance the capability of NHLBI K01, K08, K23, and K25 awardees to conduct research as they complete their transition to fully independent investigator status. This R03 grant mechanism is intended to support research projects that can be carried out and completed within a short period of time (no more than two years) with limited resources and that may generate preliminary data to support a subsequent R01-equivalent application. These studies include, but not limited to, pilot or feasibility studies; proof of concept studies; secondary analysis of existing data; small, self-contained research projects; development of new research methodologies or technologies, or development of novel experimental models. For current and previous K23 awardees, research proposed in the R03 application may or may not include patient-oriented research. A minimum of 40% protected overall research effort is required from applicants during the R03 award period and can be met through a combination of effort on the proposed R03 and other research projects, regardless of funding source.

Funding Opportunity RFA-CA-25-002 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Funding Opportunity RFA-CA-25-004 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality and handling of samples used for cancer research or clinical care. Through this NOFO, NCI will support the development of tools, devices, assays, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and address issues related to pre-analytical degradation of of targeted analytes. Major feasibility gaps for the technology or methodology should have already been overcome, as demonstrated by supportive preliminary data, but the tool requires further development and rigorous validation. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Funding Opportunity RFA-CA-25-003 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies to improve the quality and handling of samples used for cancer research or clinical care. This includes tools with new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, establish verification criteria for quality assessment/quality control, and address issues related to pre-analytical degradation of target analytes. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Funding Opportunity RFA-CA-25-001 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this NOFO is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, or epidemiology, and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Notice NOT-CA-25-006 from the NIH Guide for Grants and Contracts

Funding Opportunity PAS-25-236 from the NIH Guide for Grants and Contracts. Data science is an important cross-cutting research approach in the 2022 - 2026 NIDA Strategic Plan and increasing the capacity of experts in addiction related data science is critical. The purpose of this Notice is to facilitate the entry of investigators to the area of addiction-related data science, including newly independent data scientists or established investigators seeking to incorporate novel and cutting-edge data science methodologies into their research programs for the first time. Through this opportunity, investigators will propose to apply emerging data science methods to answer critical questions requiring advanced data analytic strategies. Projects should be small in scale and answer specific research questions or provide preliminary data for a larger scale project. Applicants are encouraged to use existing datasets, follow FAIR principles, and, when applicable, attend to ethical concerns in the conduct of research involving human subjects. Ultimately, the aim is to expedite the development of robust research programs focused on the convergence of innovative data science techniques and addiction research, with initial projects serving as precursors for subsequent, more expansive research projects.

Funding Opportunity PAR-25-311 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to leverage NICHD clinical research Network infrastructure relevant to infants, children, women, pregnant and lactating individuals, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase (UG3) and a full enrollment and clinical trial implementation phase (UH3). Applications submitted in response to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases. A UG3 project (phase I) that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award (phase II). This NOFO provides an opportunity to leverage NICHD clinical research Network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. Applications must be submitted as investigator-initiated, multi-Project Director/Principal Investigator (PD/PI) grant applications in conjunction with the respective NICHD-supported Network Data Coordinating Center (DCC), or equivalent as determined by the NICHD.

Funding Opportunity PAR-25-336 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

Funding Opportunity RFA-CA-25-019 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the NCI intends to support multi-level intervention studies that address individual and system level barriers to transition from pediatric to adult care for survivors of childhood and adolescent cancers. The goal of this opportunity is to support the development and testing of interventions and strategies that promote high-quality transitional care and continued engagement of survivors of childhood and adolescent cancers to ensure these survivors receive appropriate surveillance and care into adulthood. Overall, it is anticipated that this research will provide critical evidence for establishing best practices and standards of care that can be widely disseminated and adopted.

Funding Opportunity RFA-HG-25-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement is intended to identify and support research projects by exceptionally promising Early Stage Investigators with a long-term career interest in pursuing innovative research in genomics. This opportunity is open to research in all areas relevant to the mission of NHGRI, including genomic sciences, genomic medicine, genomic data science, and ethical, legal, and social implications of genomics.

Notice NOT-ES-25-004 from the NIH Guide for Grants and Contracts

Notice NOT-DC-25-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AA-24-012 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support the planning phase of the Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority and Other Underserved Communities. MCCI is a multi-ICO dissemination and implementation science initiative to advance health equity and end health disparities in racial/ethnic minority women and girls of reproductive age. Specifically, the Model Continuums of Care Initiative will apply the latest dissemination and implementationscience approaches to significantly reduce the prevalence and impact of multi-morbidity among racial/ethnic minority women and girls of reproductive age at risk and living with mental health disorders, substance use disorders, chronic stress, cardiopulmonary diseases, common metabolic disorders (e.g., diabetes), cancer, and HIV/AIDS. This concept proposes a continuum of care approach that integrates preventive health services, primary care, behavioral health, integrative care, and cardiopulmonary and endocrine specialties to fully address health care needs in each of these domains, and to have maximum impact on the overall health and well-being ofracial and ethnic minority and other underserved women and girls. While MCCI is not a maternal health initiative, women and girls ages 15-44 yrs. are centered because it is during the early reproductive period, i.e., adolescence, that multimorbidity typically begins and rapidly progresses, setting the stage for multiple chronic debilitating conditions in later life. Special emphasis will be placed on using stakeholder partnerships, provider training, and infrastructure changes to improve access for subgroups of racial/ethnic minority women and girls who currently have the least access to high quality health care (e.g., racial/ethnic minority women and girls living in low resource settings).

Funding Opportunity PAR-25-317 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.

Funding Opportunity PAR-25-325 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this NOFO. Extramural research funded under this NOFO may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

Funding Opportunity PAR-25-247 from the NIH Guide for Grants and Contracts. The specific purpose of this Notice of Funding Opportunity (NOFO) is to promote the development of a diverse, interdisciplinary workforce needed to conduct translational research on Alzheimer's disease and Alzheimer's-related dementias from target discovery through clinical development. This NOFO will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, behavioral research, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD/ADRD.

Notice NOT-AG-24-083 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-031 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-038 from the NIH Guide for Grants and Contracts